A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


July 8, 2011

Survey Finds Support for Universal Hep C Testing

Universal testing for hepatitis C virus (HCV) infection, as opposed to testing based on known risk factors, is the way to go, according to a survey of people attending general outpatient clinics in Seattle.

While most patients surveyed preferred to know that they were being tested and to be alerted of the results even when they were negative, the study findings, published in the June 6 issue of BMC Infectious Diseases, suggest that patients believed ensuring universal testing for HCV was more important than either soliciting patient consent for the test or providing negative test results.

The need for increased HCV testing is clear. According to U.S. Centers for Disease Control and Prevention (CDC) estimates, between 2.9 and 3.7 million people in the United States are living with HCV, yet 50 to 75 percent of them remain unaware of their status. This is problematic, given that the number of new cases of cirrhosis from HCV is expected to increase by more than 30 percent as of 2020 and subsequent liver failure, liver cancer and death will continue to increase into the 2030s--largely because of the fact that most people living with the disease do not know they are infected and, as a result, are not receiving the care and treatment they need.

With the approval of the HCV protease inhibitors--Incivek (telaprevir) and Victrelis (boceprevir)--today's HCV treatment regimens are expected to cure more than 70 percent of people living with chronic HCV infection. "Yet, despite the scale of the problem and the availability of increasingly effective treatment," write Phillip Coffin, MD, and his colleagues of the Division of Allergy and Infectious Diseases of the University of Washington in Seattle, "relatively little has been done to identify persons with HCV and ensure their treatment."

National guidelines recommend that testing for HCV be limited to people with identified risk factors, such as injection drug use, a blood transfusion before 1992, or elevated liver function tests. However, the authors suggest, "barriers to risk-based screening have resulted in inadequate detection of HCV. Most importantly, patients with a remote history of injection drug use, the primary risk factor for HCV, are often reluctant to admit that behavior to a clinician." The authors add: "In all but the most complex guidelines, risk factor--based screening also fails to account for suspected transmission routes, such as remote iatrogenic transmission [rare infections via medical procedures], intranasal drug use or even a fist fight."

But is the public ready for universal testing, which would involve testing virtually all people for HCV infection? Yes, according to the survey conducted by Coffin's group.

The survey was conducted at five outpatient clinics of a major public urban medical center in Seattle. Two hundred survey responses were received, involving a study group whose average age was 47 and more than half of which were women. Of the participants, 56.3 percent were white, roughly 33 percent were black, nearly 10 percent had tested positive for HCV and more than 2 percent had tested positive for HIV.

The survey included three options. The first, universal testing without being informed of the test or being told of negative results, was preferred by 48 percent of survey respondents. The second, testing with an opportunity to opt out and the requirement that negative results be provided, was preferred by 37 percent. The third option, which involves testing based on clinician judgment, which is most similar to current testing recommendations, was preferred by 15 percent.

"In summary," Coffin's team writes, "our findings demonstrate that patients support universal testing for HCV, as well as HIV, that an 'opt-out' program would be preferred if feasible, but that patients appear to place a higher priority on being tested than they do on the process of informed consent or the receipt of negative results. These findings should inform the priorities of clinicians, public health officials and clinical risk managers."

Search: universal testing, routine testing, hep C, survey, University of Washington, informed consent, risk

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.